Impact of Magnetic Resonance Imaging (MRI) Findings on Management of Symptomatic Patients Following Radiofrequency Ablat
- PDF / 795,431 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 50 Downloads / 183 Views
IMAGING
Impact of Magnetic Resonance Imaging (MRI) Findings on Management of Symptomatic Patients Following Radiofrequency Ablation (RFA) of Osteoid Osteoma (OO) Majid Maybody 1 & Mohamed M. Soliman 1 & Sinchun Hwang 2 & Adrian Gonzalez-Aguirre 1 & Ernesto G. Santos Martin 1 & Elena Kaye 3 & Meier Hsu 4 & Chaya Moskowitz 4 & John H. Healey 5 & Nicola Fabbri 5 Accepted: 9 September 2020 # The Author(s) 2020, corrected publication 2020
Abstract The purpose of this study is to assess the impact of MRI findings on management of symptomatic patients following RFA of OO. Retrospective review of 43 patients with RFA for OO between June 2010 and June 2017 was performed. Patient, nidus, and ablation data were reviewed. Pre- and 6–8 weeks post-procedural MRI (n = 32) were compared for coverage of nidus by ablation zone, bone marrow edema, nidus hyperintensity, and other findings. Baseline pain levels and analgesic use were compared with post-procedural follow-up visit at 6–8 weeks. Three groups of clinical and MRI outcomes of complete (CR), partial (PR), and no response (NR) were defined. A weighted kappa statistic was used to assess for agreement. Clinical responses were CR in 34/43 (79.1%, 95% CI: 64.0–90.0%), PR in 8/43 (18.6%), and NR in 1/43 (2.3%) patients. All 19/32 patients with MRI CR experienced clinical CR. One patient with MRI NR had clinical NR. All 7/32 patients with clinical PR had MRI PR. All 4/43 complications were in MRI PR or NR groups. Substantial agreement was observed between MRI and clinical outcomes (kappa: 0.69, 95% CI: 0.45–0.95). MRI helped determine etiologies in all symptomatic patients and their management (n = 8). MRI is recommended for symptomatic patients after ablation. Keywords Osteoid osteoma . Radiofrequency ablation . MRI . Clinical outcomes
* Majid Maybody [email protected]
John H. Healey [email protected] Nicola Fabbri [email protected]
Mohamed M. Soliman [email protected] Sinchun Hwang [email protected] Adrian Gonzalez-Aguirre [email protected] Ernesto G. Santos Martin [email protected] Elena Kaye [email protected] Meier Hsu [email protected] Chaya Moskowitz [email protected]
1
Department of Radiology, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave., M276C, New York, NY 10065, USA
2
Department of Radiology, Musculoskeletal Radiology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
3
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
4
Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
5
Department of Surgery, Orthopedic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
SN Compr. Clin. Med.
Introduction Osteoid osteoma (OO) accounts for 11% of all benign bone tumors affecting males twice than females. It predominantly affects patients in their first and second decades of life. It most commonly affects
Data Loading...
